SILO PHARMA, INC. Realized Investment Gains (Losses)
SILO PHARMA, INC. (SILO) reported Realized Investment Gains (Losses) of $857 for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-13.
Financial Statements › Cash Flow › Other Cash Flow Items
us-gaap:RealizedInvestmentGainsLosses · last filed 2026-08-13
- SILO PHARMA, INC. realized investment gains (losses) for the quarter ending 2026-06-30 was $857.00, a 13.35% decline year-over-year.
- SILO PHARMA, INC. realized investment gains (losses) for the quarter ending 2025-12-31 was $0.00.
- SILO PHARMA, INC. realized investment gains (losses) for the quarter ending 2025-09-30 was $0.00.
- SILO PHARMA, INC. realized investment gains (losses) for the quarter ending 2025-06-30 was $989.00.
- SILO PHARMA, INC. realized investment gains (losses) for fiscal 2022 was -$104.70K.
- SILO PHARMA, INC. realized investment gains (losses) for fiscal 2019 was $138.03K.
- SILO PHARMA, INC. realized investment gains (losses) for fiscal 2018 was -$100.76K.
- SILO PHARMA, INC. realized investment gains (losses) for fiscal 2017 was -$85.17K.
| Period end | Realized Investment Gains (Losses) 3 month | Realized Investment Gains (Losses) 6 month | Realized Investment Gains (Losses) 9 month | Realized Investment Gains (Losses) 12 month |
|---|---|---|---|---|
| 2026-06-30 | $857.00 10-Q · filed 2026-08-13 | $857.00 10-Q · filed 2026-08-13 | ||
| 2025-12-31 | $0.00 derived: POS AM 12 month − 10-Q 9 month · filed 2026-04-14 | $0.00 derived: sum of 2 quarters · filed 2026-04-14 | $989.00 derived: sum of 3 quarters · filed 2026-08-13 | $3.91K POS AM · filed 2026-04-14 |
| 2025-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-13 | $989.00 derived: sum of 2 quarters · filed 2026-08-13 | $3.91K 10-Q · filed 2025-11-13 | $3.91K derived: sum of 4 quarters · filed 2026-08-13 |
| 2025-06-30 | $989.00 10-Q · filed 2026-08-13 | $3.91K 10-Q · filed 2026-08-13 | $3.91K derived: sum of 3 quarters · filed 2026-08-13 | $3.91K derived: sum of 4 quarters · filed 2026-08-13 |
| 2025-03-31 | $2.92K 10-Q · filed 2026-05-14 | $2.92K derived: sum of 2 quarters · filed 2026-05-14 | $2.92K derived: sum of 3 quarters · filed 2026-05-14 | $1.66K derived: sum of 4 quarters · filed 2026-05-14 |
| 2024-12-31 | $0.00 derived: POS AM 12 month − 10-Q 9 month · filed 2026-04-14 | $0.00 derived: sum of 2 quarters · filed 2026-04-14 | -$1.26K derived: sum of 3 quarters · filed 2026-04-14 | -$1.02K POS AM · filed 2026-04-14 |
| 2024-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-13 | -$1.26K derived: sum of 2 quarters · filed 2025-11-13 | -$1.02K 10-Q · filed 2025-11-13 | |
| 2024-06-30 | -$1.26K 10-Q · filed 2025-08-13 | -$1.02K 10-Q · filed 2025-08-13 | ||
| 2024-03-31 | $234.00 10-Q · filed 2025-05-09 | |||
| 2023-09-30 | -$1.86K 10-Q · filed 2024-11-12 | -$4.04K derived: sum of 2 quarters · filed 2024-11-12 | -$4.04K 10-Q · filed 2024-11-12 | |
| 2023-06-30 | -$2.18K 10-Q · filed 2024-08-13 | -$2.18K 10-Q · filed 2024-08-13 | ||
| 2022-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2024-03-25 | -$104.70K 10-K · filed 2024-03-25 | ||
| 2022-09-30 | -$104.70K 10-Q · filed 2023-11-13 | |||
| 2019-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2020-03-20 | $92.26K derived: sum of 2 quarters · filed 2020-03-20 | $138.03K 10-K · filed 2020-03-20 | |
| 2019-09-30 | $92.26K derived: 10-Q 9 month − 10-Q 6 month · filed 2019-11-13 | $138.03K 10-Q · filed 2019-11-13 | ||
| 2019-06-30 | $45.77K 10-Q · filed 2019-08-13 | |||
| 2018-12-31 | $956.00 derived: 10-K 12 month − 10-Q 9 month · filed 2020-03-20 | -$622.23K derived: sum of 2 quarters · filed 2020-03-20 | -$335.01K derived: sum of 3 quarters · filed 2020-03-20 | -$100.76K 10-K · filed 2020-03-20 |
| 2018-09-30 | -$623.19K 10-Q · filed 2018-11-14 | -$335.97K derived: sum of 2 quarters · filed 2019-08-13 | -$101.72K 10-Q · filed 2019-11-13 | -$107.01K derived: sum of 4 quarters · filed 2019-08-13 |
| 2018-06-30 | $287.22K derived: 10-Q 6 month − 10-Q 3 month · filed 2019-08-13 | $521.47K 10-Q · filed 2019-08-13 | $516.18K derived: sum of 3 quarters · filed 2019-08-13 | $435.27K derived: sum of 4 quarters · filed 2019-08-13 |
| 2018-03-31 | $234.25K 10-Q · filed 2019-05-14 | $228.96K derived: sum of 2 quarters · filed 2019-05-14 | $148.05K derived: sum of 3 quarters · filed 2019-05-14 | |
| 2017-12-31 | -$5.29K derived: 10-K 12 month − 10-Q 9 month · filed 2019-04-04 | -$86.20K derived: sum of 2 quarters · filed 2019-04-04 | -$85.17K 10-K · filed 2019-04-04 | |
| 2017-09-30 | -$80.91K 10-Q · filed 2018-11-14 | -$79.88K 10-Q · filed 2018-11-14 | ||
| 2013-12-31 | $39.75K 10-K · filed 2014-03-31 | $39.75K 10-K · filed 2014-03-31 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Genprex, Inc. (GNPX) | United States | $0.003B | -0.02 |
| Alaunos Therapeutics, Inc. (TCRT) | United States | $0.003B | -1.44 |
| GeoVax Labs, Inc. (GOVX) | United States | $0.003B | -0.45 |
| Petros Pharmaceuticals, Inc. (PTPI) | United States | $0.003B | |
| Sunshine Biopharma Inc. (SBFM) | $0.003B | ||
| Matinas BioPharma Holdings, Inc. (MTNB) | United States | $0.003B | |
| ZyVersa Therapeutics, Inc. (ZVSA) | United States | $0.002B | |
| Aptevo Therapeutics Inc. (APVO) | United States | $0.003B | |
| BioXcel Therapeutics, Inc. (BTAI) | United States | $0.002B | |
| JUPITER NEUROSCIENCES, INC. (JUNS) | United States | $0.002B | -0.02 |